Welcome to the “Get to know the UNIVERSAL project” series! Here we will introduce you to the various work packages and facets that make up the UNIVERSAL project. The UNIVERSAL-Relative Bioavailability (RBA) sub-study will inform the UNIVERSAL 1 trial which aims to...
Welcome to the of the “Get to know the UNIVERSAL project” series! Here we will introduce you to the various work packages and facets that make up the UNIVERSAL project. Pharmacokinetic study of new DTC, FTC, TAF dose ratio (Work package 3) Within the...
Welcome to the “Get to know the UNIVERSAL project” series! Here we will introduce you to the various work packages and facets that make up the UNIVERSAL project. Assessing the long-term safety of ART drugs (Work package 5) Prompt treatment of children living...
Four early career researchers in the field of paediatric HIV recently received the CIPHER Growing the Leaders of Tomorrow Fellowship and the UNIVERSAL Student Research and Capacity Building grant. As beneficiaries of these awards, these young doctors will receive...
The UNIVERSAL project conducted a Training Needs Assessment (TNA) from March 17th to June 21st 2021 among 108 African early career researchers from Cameroon, Mali, Senegal, Uganda and Zimbabwe who are involved in the project
Development is underway based on an agreement launched in June 2021 between Unitaid, the Clinton Health Access Initiative (CHAI), and pharmaceutical manufacturer Laurus Labs to accelerate the development, commercialization, and registration of the best-in-class...
A while ago, we sat with Marc Lallemant – the scientific coordinator of the UNIVERSAL project led by Penta, for a quick chat. It was an eye-opening discussion that delved into the early beginnings and the birth of the project. According to Marc, TUTI pronounced as...
Penta is the coordinator for the newly funded EDCTP project – UNIVERSAL! Later in the day, we will be speaking with partners at the official kick-off meeting.
UNIVERSAL will develop, evaluate and register two new antiretroviral formulations for infants and children newly diagnosed with HIV initiating antiretroviral therapy, and for children failing first-line therapy who need to switch to a new treatment regimen.
